Clofarabine, Idarubicin, and Cytarabine Combination as Induction Therapy for Younger Patients With Acute Myeloid Leukemia (AML).

Trial Profile

Clofarabine, Idarubicin, and Cytarabine Combination as Induction Therapy for Younger Patients With Acute Myeloid Leukemia (AML).

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2013

At a glance

  • Drugs Clofarabine (Primary) ; Cytarabine (Primary) ; Idarubicin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 09 Mar 2011 New source identified and integrated (M.D. Anderson Cancer Center).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top